Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;54(6):4466-4476.
doi: 10.1007/s12035-016-9993-0. Epub 2016 Jun 28.

Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders

Maria Sara Cipolat Mis  1 , Simona Brajkovic  1 , Francesco Tafuri  1 , Nereo Bresolin  1 , Giacomo P Comi  1 , Stefania Corti  2
Affiliations
Free article
Review

Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders

Maria Sara Cipolat Mis et al. Mol Neurobiol. 2017 Aug.
Free article

Abstract

The identification of the hexanucleotide repeat expansion (HRE) GGGGCC (G4C2) in the non-coding region of the C9ORF72 gene as the most frequent genetic cause of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) has opened the path for advances in the knowledge and treatment of these disorders, which remain incurable. Recent evidence suggests that HRE RNA can cause gain-of-function neurotoxicity, but haploinsufficiency has also been hypothesized. In this review, we describe the recent developments in therapeutic targeting of the pathological expansion of C9ORF72 for ALS, FTD, and other neurodegenerative disorders. Three approaches are prominent: (1) an antisense oligonucleotides/RNA interference strategy; (2) using small compounds to counteract the toxic effects directly exerted by RNA derived from the repeat transcription (foci), by the translation of dipeptide repeat proteins (DPRs) from the repeated sequence, or by the sequestration of RNA-binding proteins from the C9ORF72 expansion; and (3) gene therapy, not only for silencing the toxic RNA/protein, but also for rescuing haploinsufficiency caused by the reduced transcription of the C9ORF72 coding sequence or by the diminished availability of RNA-binding proteins that are sequestered by RNA foci. Finally, with the perspective of clinical therapy, we discuss the most promising progress that has been achieved to date in the field.

Keywords: Antisense oligonucleotides; Haploinsufficiency; Hexanucleotide repeat expansion.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):E4530-9 - PubMed
    1. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7778-83 - PubMed
    1. PLoS Genet. 2010 Dec 09;6(12):e1001240 - PubMed
    1. Nat Rev Neurol. 2015 Dec;11(12):670-2 - PubMed
    1. Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11748-53 - PubMed

Publication types

MeSH terms

Substances